Literature DB >> 16423879

Lives and times of nuclear receptors.

Elaine T Alarid1.   

Abstract

Down-regulation of receptor in response to ligand was one of the earliest functional readouts of steroid hormone action. The loss of total receptor content upon stimulation, referred to initially as receptor "processing," was carefully described with respect to receptor nuclear transformation or tight nuclear binding. It was these early studies that were the first to note a correlation between receptor turnover and induction of gene transcription, leading to the proposal that down-regulation of receptor was involved in mechanisms of transcriptional activation. This idea has now attracted renewed attention with the discovery that ligand-induced "processing" in the form of proteolysis is carried out by the 26S proteasome, a multicatalytic enzyme whose activity is directly coupled to cell-cycle control, signal transduction, and importantly, transcription. Here, we review our current understanding of the mechanism and relevance of proteolysis to receptor function based on general concepts that have emerged from analyses of liganded members of the nuclear receptor family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423879     DOI: 10.1210/me.2005-0481

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  31 in total

1.  Nuclear receptors CAR and PXR in the regulation of hepatic metabolism.

Authors:  E S Tien; M Negishi
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 2.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

3.  Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.

Authors:  P Rajbhandari; K A Schalper; N M Solodin; S J Ellison-Zelski; K Ping Lu; D L Rimm; E T Alarid
Journal:  Oncogene       Date:  2013-04-01       Impact factor: 9.867

4.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

5.  Ligand-induced repression of the glucocorticoid receptor gene is mediated by an NCoR1 repression complex formed by long-range chromatin interactions with intragenic glucocorticoid response elements.

Authors:  Sivapriya Ramamoorthy; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

6.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

7.  Differential fibroblast growth factor 8 (FGF8)-mediated autoregulation of its cognate receptors, Fgfr1 and Fgfr3, in neuronal cell lines.

Authors:  Natasha N Mott; Wilson C J Chung; Pei-San Tsai; Toni R Pak
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

8.  HACE1: A novel repressor of RAR transcriptional activity.

Authors:  Jianhua Zhao; Zhenping Zhang; Zivjena Vucetic; Kenneth J Soprano; Dianne Robert Soprano
Journal:  J Cell Biochem       Date:  2009-06-01       Impact factor: 4.429

9.  Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.

Authors:  A-Young Jo; Mi-Young Kim; Hyun-Seob Lee; Yong-Hee Rhee; Jeong-Eun Lee; Kwang-Hyun Baek; Chang-Hwan Park; Hyun-Chul Koh; Incheol Shin; Yong-Sung Lee; Sang-Hun Lee
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.